Literature DB >> 8982509

Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro.

M Connor1, C W Vaughan, B Chieng, M J Christie.   

Abstract

1. In this study we have examined the effects of nociceptin, an endogenous ligand for the opioid-like receptor ORL1 on the membrane properties of rat locus coeruleus (LC) neurones in vitro, using intracellular and whole cell patch clamp recording. 2. When locus coeruleus neurones were voltage clamped to -60 mV, application to nociceptin caused an outward current in all cells examined (n = 49), with an EC50 of 90 nM. Neither the potency nor the maximal effect of nociceptin was altered in the presence of the peptidase inhibitors, bestatin (20 microM) or thiorphan (2 microM). 3. The outward currents caused by nociceptin in 2.5 mM extracellular K+ reversed polarity at -123 mV, more negative than the predicted K+ reversal potential of -105 mV. Increasing extracellular K+ to 6.5 mM resulted in a shift of the reversal potential of +25 mV, a shift consistent with a K+ conductance. The conductance activated by nociceptin showed mild inward rectification. 4. Application of a high concentration of nociceptin (3 microM) occluded the current produced by simultaneous application of high concentrations of Met-enkephalin (10 microM), (3 microM) somatostatin and UK 14304 (3 microM), indicating that nociceptin activated the same conductance as mu-opioid and somatostatin receptors and alpha 2-adrenoceptors. 5. The actions of nociceptin were weakly antagonized by the opioid antagonist, naloxone, with pKb's estimated from 2 cells of -4.23 and -4.33. The mu-opioid antagonist, CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Pen-Thr-NH2, 1 microM), the opioid antagonist, nalorphine (30 microM) or the somatostatin antagonist, CPP (cyclo(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bz1]) 3 microM) did not affect the nociceptin-induced current. 6. Dynorphin A (microM), another putative endogenous ligand for ORL1, caused a robust outward current in locus coeruleus neurones that was, however, completely antagonized by moderate concentrations of naloxone (300 nM-1 microM). 7. Continuous application of nociceptin (3 microM) resulted in a decrease of the outward current to a steady level of 70% of the maximum response with a t1/2 of 120s. Desensitization was largely homologous because simultaneous application of Met-enkephalin (30 microM) during the desensitized period of the nociceptin response resulted in an outward current that was 92% of control responses to Met-enkephalin in the same cells. Conversely, continuous application of Met-enkephalin (30 microM) resulted in a decrease of Met-enkephalin current to a steady level that was 54% of the initial current. During this desensitized period application of nociceptin (3 microM) resulted in a current that was 78% of the control responses to nociceptin in the same cells. 8. Thus nociceptin potently activates an inwardly rectifying K+ conductance in locus coeruleus neurones, with a pharmacological profile consistent with activation of the ORL1 receptor. Dynorphin A does not appear to be a ligand for ORL1 in rat locus coeruleus neurones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982509      PMCID: PMC1915781          DOI: 10.1111/j.1476-5381.1996.tb16080.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  On the potassium conductance increased by opioids in rat locus coeruleus neurones.

Authors:  R A North; J T Williams
Journal:  J Physiol       Date:  1985-07       Impact factor: 5.182

2.  Multiple opioid receptors: ligand selectivity profiles and binding site signatures.

Authors:  A Goldstein; A Naidu
Journal:  Mol Pharmacol       Date:  1989-08       Impact factor: 4.436

3.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor.

Authors:  C Chavkin; I F James; A Goldstein
Journal:  Science       Date:  1982-01-22       Impact factor: 47.728

4.  Enkephalin opens potassium channels on mammalian central neurones.

Authors:  J T Williams; T M Egan; R A North
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

5.  Opiates and opioid peptides hyperpolarize locus coeruleus neurons in vitro.

Authors:  C M Pepper; G Henderson
Journal:  Science       Date:  1980-07-18       Impact factor: 47.728

6.  Somatostatin induces an inward rectification in rat locus coeruleus neurones through a pertussis toxin-sensitive mechanism.

Authors:  M Inoue; S Nakajima; Y Nakajima
Journal:  J Physiol       Date:  1988-12       Impact factor: 5.182

7.  Opioid inhibition of rat periaqueductal grey neurones with identified projections to rostral ventromedial medulla in vitro.

Authors:  P B Osborne; C W Vaughan; H I Wilson; M J Christie
Journal:  J Physiol       Date:  1996-01-15       Impact factor: 5.182

8.  Transient homologous mu-opioid receptor desensitization in rat locus coeruleus neurons.

Authors:  G C Harris; J T Williams
Journal:  J Neurosci       Date:  1991-08       Impact factor: 6.167

9.  Voltage- and ligand-activated inwardly rectifying currents in dorsal raphe neurons in vitro.

Authors:  J T Williams; W F Colmers; Z Z Pan
Journal:  J Neurosci       Date:  1988-09       Impact factor: 6.167

10.  Potentiation of enkephalin action by peptidase inhibitors in rat locus ceruleus in vitro.

Authors:  J T Williams; M J Christie; R A North; B P Roques
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

View more
  51 in total

1.  Nociceptin inhibits T-type Ca2+ channel current in rat sensory neurons by a G-protein-independent mechanism.

Authors:  F A Abdulla; P A Smith
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

Review 2.  Mu-opioid receptor desensitization: is morphine different?

Authors:  Mark Connor; Peregrine B Osborne; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

3.  Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.

Authors:  Erica S Levitt; Lauren C Purington; John R Traynor
Journal:  Mol Pharmacol       Date:  2010-11-22       Impact factor: 4.436

Review 4.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

5.  Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons.

Authors:  F A Abdulla; P A Smith
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

6.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

7.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

Review 8.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

9.  Novel role of the nociceptin system as a regulator of glutamate transporter expression in developing astrocytes.

Authors:  Logan C Meyer; Caitlin E Paisley; Esraa Mohamed; John W Bigbee; Tomasz Kordula; Hope Richard; Kabirullah Lutfy; Carmen Sato-Bigbee
Journal:  Glia       Date:  2017-09-14       Impact factor: 7.452

10.  The role of NOP receptors in psychomotor stimulation and locomotor sensitization induced by cocaine and amphetamine in mice.

Authors:  Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.